The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
Agostina Nardone(AstraZeneca (Spain)), Rachel Schiff(Baylor College of Medicine), Carmine De Angelis(Baylor College of Medicine), Gary C. Chamness(Baylor College of Medicine), C. Kent Osborne(Baylor College of Medicine), Maria Letizia Cataldo(Baylor College of Medicine), Mark Pilling(AstraZeneca (United Kingdom)), Meghana V. Trivedi(University of Houston), Hazel M. Weir(AstraZeneca (United Kingdom)), Chandandeep Nagi(Icahn School of Medicine at Mount Sinai), Rinath Jeselsohn(Dana-Farber Cancer Institute), Xiaoyong Fu(King University), Jamunarani Veeraraghavan(Baylor College of Medicine), Mothaffar F. Rimawi(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), H. Shelton Brown(AstraZeneca (United Kingdom)), Martin J. Shea(Baylor College of Medicine), Tamika Mitchell(Baylor College of Medicine), Oona Delpuech(AstraZeneca (United Kingdom))
Cited by 65
Related Papers
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
|Cancer Research|2008|494